Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03188185 · ClinicalTrials.gov registry record · Phase 3
A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)
A Phase 3 study, sponsored by Alkermes.
- Completed
- Registry status
- Phase 3
- Development phase
- 278
- Enrollment target
NCT03188185 is a Phase 3 study that has completed, run by Alkermes. The registered enrollment target is 278 participants.
The verdict
NCT03188185, a Phase 3 study, has completed, sponsored by Alkermes.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 278 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.
Interventions
- DRUG ALKS 5461
- DRUG ALKS 5461 Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 278 participants |
| Start Date | 2017-06-12 |
| Est. Completion | 2020-03-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03188185
The ClinicalTrials.gov registry entry for NCT03188185 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 278 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alkermes, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ALKS 5461 is the first listed.
NCT03188185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03188185 about?
NCT03188185 is a clinical study titled "A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD)". This study will evaluate the efficacy, safety, and tolerability of adjunctive ALKS 5461 in adults who have treatment refractory MDD.
What is the current status of trial NCT03188185?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 278 participants. The study started on 2017-06-12. Estimated completion is 2020-03-05.
What interventions are being tested in trial NCT03188185?
The interventions under investigation include: ALKS 5461 (DRUG), ALKS 5461 Placebo (DRUG).
Who is sponsoring clinical trial NCT03188185?
This trial is sponsored by Alkermes, which has 66 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.